Skip to Content

Real-World Data on Avelumab as 1L Maintenance Treatment

In this MEDtalk, Dr. Philippe Barthelemy from the ICANS Institute in Strasbourg, discusses the results from the AVENANCE study with real-world data from France. The study confirms the effectiveness and safety of avelumab as a safe standard of care for patients with advanced urothelial carcinoma.

Philippe Barthelemy

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top